We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Focus: What Axinn's Practice Chair Is Watching

Law360 (September 14, 2018, 4:32 PM EDT) -- Chad Landmon, head of the U.S. Food and Drug Administration practice at Axinn Veltrop & Harkrider LLP, tells Law360 he's been urging regulators to make drug exclusivity decisions more quickly, looking for clarity on biosimilar approval standards and preparing for the U.S. Supreme Court to curb judicial deference to the FDA.

Chad Landmon

Landmon has been with Axinn for 18 years — virtually his entire career since earning his J.D. from the University of Connecticut School of Law. He focuses heavily on litigation involving drug patents...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.